Analysis of stromal cells in osteofibrous dysplasia and adamantinoma of long bones - PubMed

Analysis of stromal cells in osteofibrous dysplasia and adamantinoma of long bones

Richard M Taylor et al. Mod Pathol. 2012 Jan.

Free article

Abstract

Adamantinoma of long bones and osteofibrous dysplasia are rare, osteolytic primary bone tumours of uncertain origin containing areas of fibrous and fibro-osseous proliferation. We investigated the nature of the stromal cells in adamantinoma of long bones and osteofibrous dysplasia, and determined cellular and molecular mechanisms of osteolysis in these tumours. Cell culture, molecular (RT-PCR, western blot) and immunohistochemical studies on cases of adamantinoma of long bones and of osteofibrous dysplasia were undertaken to determine the expression of epithelial, osteoblast and osteoclast markers. Ultrastructural and immunophenotypic studies on cultured adamantinoma and osteofibrous dysplasia stromal cells showed that these cells were mainly fibroblast-like with few cells expressing epithelial markers. Osteofibrous dysplasia but not adamantinoma cells expressed alkaline phosphatase. Both osteofibrous dysplasia and adamantinoma cells expressed the ostoclastogenic factors M-CSF and RANKL. Adamantinoma and osteofibrous dysplasia cells also expressed messenger RNA for osteocalcin, osteonectin, osteopontin, osterix and collagen type 1. Adamantinoma and osteofibrous dysplasia cells cultured alone on dentine slices were not capable of lacunar resorption, but in co-cultures with monocytes induced formation of osteoclast-like cells was observered. Cultured osteofibrous dysplasia and adamantinoma stromal cells show similar ultrastructural and immunophenotypic characteristics, and differentially express osteoblast markers. Promotion of osteoclastogenesis by stromal cells may contribute to osteolysis in adamantinoma of long bones and osteofibrous dysplasia.

Similar articles

• Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia.

  Kashima TG, Dongre A, Flanagan AM, Hogendoorn PC, Taylor R, Athanasou NA. Kashima TG, et al. Virchows Arch. 2011 Jul;459(1):41-6. doi: 10.1007/s00428-011-1081-2. Epub 2011 Apr 16. Virchows Arch. 2011. PMID: 21499851

• p63 expression in adamantinoma.

  Dickson BC, Gortzak Y, Bell RS, Ferguson PC, Howarth DJ, Wunder JS, Kandel RA. Dickson BC, et al. Virchows Arch. 2011 Jul;459(1):109-13. doi: 10.1007/s00428-011-1101-2. Epub 2011 Jun 15. Virchows Arch. 2011. PMID: 21674157

• Osteofibrous dysplasia-like adamantinoma of bone: a report of five cases with immunohistochemical and ultrastructural studies.

  Kuruvilla G, Steiner GC. Kuruvilla G, et al. Hum Pathol. 1998 Aug;29(8):809-14. doi: 10.1016/s0046-8177(98)90449-x. Hum Pathol. 1998. PMID: 9712421

• Juvenile intracortical adamantinoma of the tibia with predominant osteofibrous dysplasia-like features.

  Ueda Y, Roessner A, Bosse A, Edel G, Böcker W, Wuisman P. Ueda Y, et al. Pathol Res Pract. 1991 Dec;187(8):1039-43; discussion 1043-4. doi: 10.1016/s0344-0338(11)81081-2. Pathol Res Pract. 1991. PMID: 1724319 Review.

• Osteofibrous dysplasia and adamantinoma.

  Most MJ, Sim FH, Inwards CY. Most MJ, et al. J Am Acad Orthop Surg. 2010 Jun;18(6):358-66. doi: 10.5435/00124635-201006000-00008. J Am Acad Orthop Surg. 2010. PMID: 20511441 Review.

Cited by

• MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone.

  Wang T, Yin H, Wang J, Li Z, Wei H, Liu Z, Wu Z, Yan W, Liu T, Song D, Yang X, Huang Q, Zhou W, Xiao J. Wang T, et al. Oncotarget. 2015 Aug 7;6(22):18980-96. doi: 10.18632/oncotarget.4223. Oncotarget. 2015. PMID: 26053181 Free PMC article.

• Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia.

  Gray MJ, Kannu P, Sharma S, Neyt C, Zhang D, Paria N, Daniel PB, Whetstone H, Sprenger HG, Hammerschmidt P, Weng A, Dupuis L, Jobling R, Mendoza-Londono R, Dray M, Su P, Wilson MJ, Kapur RP, McCarthy EF, Alman BA, Howard A, Somers GR, Marshall CR, Manners S, Flanagan AM, Rathjen KE, Karol LA, Crawford H, Markie DM, Rios JJ, Wise CA, Robertson SP. Gray MJ, et al. Am J Hum Genet. 2015 Dec 3;97(6):837-47. doi: 10.1016/j.ajhg.2015.11.001. Am J Hum Genet. 2015. PMID: 26637977 Free PMC article.

• Adamantinoma: An Updated Review.

  Varvarousis DN, Skandalakis GP, Barbouti A, Papathanakos G, Filis P, Tepelenis K, Kitsouli A, Kanavaros P, Kitsoulis P. Varvarousis DN, et al. In Vivo. 2021 Nov-Dec;35(6):3045-3052. doi: 10.21873/invivo.12600. In Vivo. 2021. PMID: 34697136 Free PMC article. Review.

• Focal fibrocartilaginous dysplasia in the thoracic vertebra: A case report.

  Sun B, Zhang ZH, Chen XY, Huang SH, Liu ZL. Sun B, et al. Oncol Lett. 2014 Oct;8(4):1539-1542. doi: 10.3892/ol.2014.2331. Epub 2014 Jul 9. Oncol Lett. 2014. PMID: 25202364 Free PMC article.

• Recurrent Adamantinoma With Fibrous Dysplasia-like Feature.

  Petaros A, Šantić V, Vuković AS, Perić P, Jonjić N. Petaros A, et al. Clin Pathol. 2024 Apr 7;17:2632010X241240391. doi: 10.1177/2632010X241240391. eCollection 2024 Jan-Dec. Clin Pathol. 2024. PMID: 38595806 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Research Materials

  • NCI CPTC Antibody Characterization Program